Difference between revisions of "High-level Concepts v0.2"
Jump to navigation
Jump to search
m |
m |
||
(3 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | Go back to [[ | + | Go back to [[OCI:Main Page]] |
==High-Level Concepts version 0.2== | ==High-Level Concepts version 0.2== | ||
Line 7: | Line 7: | ||
Additions from Richard in <font style=color:green>green</font> font | Additions from Richard in <font style=color:green>green</font> font | ||
+ | |||
+ | Additions from Wenle and Jim in <font style=color:orange>orange</font> font | ||
*Events | *Events | ||
*Periods | *Periods | ||
**Study phases | **Study phases | ||
+ | ***<font style="color:orange">patient screening phase - reach out patients for potential study subjects | ||
+ | ***subject enrollment phase - obtain informed consent for eligible subejcts | ||
+ | ***baseline phase - perform assessment before study treatment | ||
+ | ***treatment phase - treat study subjects | ||
+ | ***follow-up phase - obtain assessments after study treatment</font> | ||
**Protocol phases | **Protocol phases | ||
*Sequence of events | *Sequence of events | ||
Line 33: | Line 40: | ||
</font> | </font> | ||
*Research types | *Research types | ||
− | **<font style="color:blue">Randomized Clinical Trial</font> | + | **<font style="color:blue">Randomized Clinical Trial</font><font style="color:orange"> - can we change this term to "Clinical Trial"? |
+ | ***phase I - dose finding, safety | ||
+ | ***phase II - dose finding - efficacy | ||
+ | ****phase II a - small scale feasibility | ||
+ | ****phase II b - randomized comparative using intermediate endpoints | ||
+ | ***phase III trial - Randomized comparative with definitive clinical endpoints | ||
+ | ***phase IV trial - post marketing safety and efficacy | ||
+ | </font> | ||
*Methods | *Methods | ||
*Stakeholders | *Stakeholders | ||
Line 47: | Line 61: | ||
***Eligible population | ***Eligible population | ||
***Screened population</font> | ***Screened population</font> | ||
+ | ***<font style="color:orange">Completer population | ||
+ | ***Premature termination population</font> | ||
**<font style="color:blue">Excluded population | **<font style="color:blue">Excluded population | ||
***Excluded postrandomization population | ***Excluded postrandomization population | ||
Line 57: | Line 73: | ||
***Crossover population | ***Crossover population | ||
***Subgroup population</font> | ***Subgroup population</font> | ||
+ | ***<font style="color:orange">Intent-to-treat population - based on randomization | ||
+ | ***per-protocol population - exclude those with servious protocol violations</font> | ||
*Variables | *Variables | ||
**Independent variable | **Independent variable | ||
Line 74: | Line 92: | ||
****Adverse event/Side effect | ****Adverse event/Side effect | ||
****Ancillary outcome</font> | ****Ancillary outcome</font> | ||
+ | ****<font style="color:orange">efficacy assessment | ||
+ | ****safety assessment | ||
+ | *****adverse events | ||
+ | ******severity | ||
+ | ******relationship to study treatment | ||
+ | ******serious</font> | ||
*Digital and paper artifacts | *Digital and paper artifacts | ||
*Protocol | *Protocol | ||
Line 107: | Line 131: | ||
*Participant characteristic (phenotype) | *Participant characteristic (phenotype) | ||
**<font style="color:blue">Baseline characteristic</font> | **<font style="color:blue">Baseline characteristic</font> | ||
− | |||
− | |||
− | |||
− | |||
− |
Latest revision as of 10:54, 6 July 2007
Go back to OCI:Main Page
High-Level Concepts version 0.2
Initial High-level Concepts in black font
Additions from Simona in blue font
Additions from Richard in green font
Additions from Wenle and Jim in orange font
- Events
- Periods
- Study phases
- patient screening phase - reach out patients for potential study subjects
- subject enrollment phase - obtain informed consent for eligible subejcts
- baseline phase - perform assessment before study treatment
- treatment phase - treat study subjects
- follow-up phase - obtain assessments after study treatment
- Protocol phases
- Study phases
- Sequence of events
- Study designs
- Descriptive research – research in which the investigator attempts to describe a group of individuals based on a set of variable in order to document their characteristics
- Case study – description of one or more patients
- Developmental research – description of pattern of change over time
- Normative research – establishing normal values
- Qualitative research – gathering data through interview or observation
- Evaluation research – objectively assess a program or policy by describing the needs for the services or policy, often using surveys or questionaires
- Exploratory research
- Cohort or case-control studies – establish associations through epidemiological studies
- Methodological studies – establish reliability and validity of a new method
- Secondary analysis – exploring new relationships in old data
- Historical research – reconstructing the past through an assessment of archives or other records
- Experimental research
- Randomized clinical trial – controlled comparison of an experimental intervention allowing the assessment of the causes of outcomes
- Single-subject design
- Sequential clinical trial
- Evaluation research – assessment of the success of a program or policy
- Quasi-experimental research
- Meta-analysis – statistically combining findings from several different studies to obtain a summary analysis
- Randomized clinical trial – controlled comparison of an experimental intervention allowing the assessment of the causes of outcomes
- Descriptive research – research in which the investigator attempts to describe a group of individuals based on a set of variable in order to document their characteristics
- Research types
- Randomized Clinical Trial - can we change this term to "Clinical Trial"?
- phase I - dose finding, safety
- phase II - dose finding - efficacy
- phase II a - small scale feasibility
- phase II b - randomized comparative using intermediate endpoints
- phase III trial - Randomized comparative with definitive clinical endpoints
- phase IV trial - post marketing safety and efficacy
- Randomized Clinical Trial - can we change this term to "Clinical Trial"?
- Methods
- Stakeholders
- Participants
- Investigators
- Monitors
- Study committee
- Sponsors
- Populations
- Recruited population
- Randomized population
- Enrolled population
- Eligible population
- Screened population
- Completer population
- Premature termination population
- Excluded population
- Excluded postrandomization population
- Not-randomized-population
- Not-enrolled-population
- Not-eligible-population
- Analyzed-population
- All subjects
- Study arm population
- Crossover population
- Subgroup population
- Intent-to-treat population - based on randomization
- per-protocol population - exclude those with servious protocol violations
- Recruited population
- Variables
- Independent variable
- Intervention
- Procedure
- Device implantation
- Drug treatment
- Placebo treatment
- Sham procedure
- Usual care
- Counseling
- Cointervention
- Intervention
- Dependent variable (responding variable)
- Outcome
- Primary outcome
- Secondary outcome
- Adverse event/Side effect
- Ancillary outcome
- efficacy assessment
- safety assessment
- adverse events
- severity
- relationship to study treatment
- serious
- adverse events
- Outcome
- Independent variable
- Digital and paper artifacts
- Protocol
- Intended protocol
- Executed protocol
- Protocol change
- Protocol application
- Assessments
- Experimental assays
- Observations
- Physical exam
- Interview
- Self-assessments
- Data analysis
- Data partitioning
- Data transformation
- Data pooling
- Data summarization
- Reliability
- Correlation
- Specimen processing
- Procurement
- Specimen partitioning/purification
- Specimen storage
- Treatment assignment
- Blinding
- Follow-up
- Assessments
- Measurement scale
- Nominal
- Ordinal
- Interval
- Ratio
- Participant characteristic (phenotype)
- Baseline characteristic